Application of serum protein marker combination to colorectal cancer screening, diagnosis and treatment

A colorectal cancer and protein technology, which is applied in the application field of serum protein marker combination in colorectal cancer screening, diagnosis and treatment, can solve the problems of unsuitability for tumor patients, low sensitivity, and difficult tumor carcinogenesis.

Inactive Publication Date: 2018-12-25
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Fecal occult blood test (FOBT) is currently a simple and economical screening method, but its sensitivity is low, it is not suitable for non-bleeding tumor patients, and the compliance and efficiency of census are still low, resulting in a large number of results. Missed diagnosis of early rectal cancer patients
Currently, the gold standard for the diagnosis of colorectal cancer is biopsy and histopathological examination of lesion tissue under fiberoptic colonoscopy, but it is diffic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of serum protein marker combination to colorectal cancer screening, diagnosis and treatment
  • Application of serum protein marker combination to colorectal cancer screening, diagnosis and treatment
  • Application of serum protein marker combination to colorectal cancer screening, diagnosis and treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Example 1: Sensitivity and specificity of protein combinations in serum samples from patients with colorectal cancer

[0079] For 173 patients with colorectal cancer confirmed by histopathological diagnosis (colon cancer patients or rectal cancer patients, not particularly distinguishing early or late stage) and 115 normal human serum samples, ELISA method was used to detect CA19-9, CEA, HGF , IP-10, MIP-1β and SDF-1α six protein levels, and analyzed.

[0080] The experimental results are shown in Table 1, Table 2 and Figure 1A - Figure 1F shown.

[0081] Table 1: Sensitivity and specificity of individual proteins in colorectal cancer

[0082]

[0083]

[0084] All samples are valid samples.

[0085] Table 2: Sensitivity and specificity of protein combinations in colorectal cancer

[0086]

[0087] Note: 6 out of 2 positive means 2 out of 6 antibodies are positive; 5 out of 2 positive means 2 out of 5 antibodies are positive; 2 out of 2 positive means ...

Embodiment 2

[0089] Example 2: Sensitivity of protein-antibody combination in the detection of colon cancer serum samples

[0090] For 24 patients with colon cancer confirmed by histopathological diagnosis, the levels of six proteins, CA19-9, CEA, HGF, IP-10, MIP-1β and SDF-1α, were detected and analyzed by ELISA.

[0091] The experimental results are shown in Table 3 and Table 4 and Figure 2A-Figure 2F shown.

[0092] Table 3: Sensitivity of individual proteins in colon cancer

[0093] protein name

Number of positive cases

sensitivity

CA19-9

8

33.33％

CEA

11

45.83％

HGF

7

29.17％

IP-10

8

33.33％

MIP-1β

6

25.00％

SDF-1α

6

25.00％

[0094] Note: All samples are valid samples.

[0095] Table 4: Sensitivity of protein combinations in colon cancer

[0096]

[0097] Note: 6 out of 2 positive means 2 out of 6 antibodies are positive; 5 out of 2 positive means 2 out of 5 antibodies are positive...

Embodiment 3

[0099] Example 3: Sensitivity of protein-antibody combination in the detection of rectal cancer serum samples

[0100] For 89 patients with rectal cancer confirmed by histopathological diagnosis, the levels of six proteins, CA19-9, CEA, HGF, IP-10, MIP-1β and SDF-1α, were detected and analyzed by ELISA.

[0101] The experimental results are shown in Table 5 and Table 6 and Figure 3A-Figure 3F shown.

[0102] Table 5: Sensitivity of individual proteins in rectal cancer

[0103] protein name

Number of positive cases

sensitivity

CA19-9

30

33.71％

CEA

55

61.80％

HGF

33

37.08％

IP-10

31

34.83％

MIP-1β

33

37.08％

SDF-1α

32

35.96％

[0104] All samples are valid samples.

[0105] Table 6: Sensitivity of protein combinations in rectal cancer

[0106]

[0107] Note: 6 out of 2 positive means 2 out of 6 antibodies are positive; 5 out of 2 positive means 2 out of 5 antibodies are posit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of molecular biology and clinical detection, and relates to a protein combination, wherein the protein combination is selected from any two or three or four or five or six of CA19-9, CEA, HGF, IP-10, MIP-1beta and SDF-1alpha. The invention further relates to a ligand combination specifically bound with proteins in the protein combination, and application of the protein combination or the ligand combination to preparation of a kit for colorectal cancer screening, auxiliary diagnosis, treatment monitoring and prognosis judging. A serum protein markercombination can be used for colorectal cancer screening, auxiliary diagnosis, treatment monitoring and prognosis judging and particularly used for early colorectal cancer screening and auxiliary diagnosis, and the sensitivity of the serum protein marker combination is superior to that of a single protein marker and commonly used clinical serum markers CA19-9 and CEA in detecting.

Description

technical field [0001] The invention belongs to the technical field of molecular biology and clinical detection, in particular, it relates to a marker combination comprising six proteins selected from CA19-9, CEA, HGF, IP-10, MIP-1β and SDF-1α, and the marker Application of the compound combination in preparation of serum marker kits for colorectal screening, auxiliary diagnosis, treatment monitoring and prognosis judgment. Background technique [0002] Colorectal cancer is one of the most common malignant tumors in the world today, posing a great threat to human health and life. In my country, according to the latest data from the National Cancer Center, there were 331,300 new cases of colorectal cancer in China in 2012, with an incidence rate of 24.47 / 10 6 ;Death cases were 159,300, and the death rate was 11.77 / 10 6 , its morbidity and mortality rank fourth and fifth respectively. Most patients are already in the advanced stage when they are diagnosed. The 5-year surviv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68G01N33/574
CPCG01N33/57419G01N33/57446G01N33/6803
Inventor 王明荣郝佳洁常晨张钰徐昕蔡岩
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap